Lynx1 Capital Management’s TScan Therapeutics TCRX Stock Holding History

Lynx1 Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.86M	Hold	8,019,148	–	–	0.91%	7
2026 Q1	$8.1M	Hold	8,019,148	–	–	1.28%	8
2025 Q4	$8.02M	Buy	8,019,148 +161,801	+2%	+$234K	1.62%	8
2025 Q3	$14.3M	Hold	7,857,347	–	–	2.91%	7
2025 Q2	$11.4M	Buy	7,857,347 +2,500,000	+47%	+$3.61M	3.29%	7
2025 Q1	$7.39M	Hold	5,357,347	–	–	2.65%	8
2024 Q4	$16.3M	Buy	5,357,347 +132,747	+3%	+$602K	6.11%	6
2024 Q3	$26M	Hold	5,224,600	–	–	9.22%	5
2024 Q2	$30.6M	Hold	5,224,600	–	–	11.03%	5
2024 Q1	$41.5M	Hold	5,224,600	–	–	10.68%	4
2023 Q4	$30.5M	Hold	5,224,600	–	–	11.98%	4
2023 Q3	$13.4M	Hold	5,224,600	–	–	8.85%	5
2023 Q2	$13.1M	Buy	+5,224,600	New	+$14M	8.56%	5

Other funds holding TCRX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Lynx1 Capital Management's TCRX Position: Q2 2026 in Review

Lynx1 Capital Management held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 8,019,148 shares worth $7.86M. The position accounts for 0.91% of the portfolio, ranked #7.

Lynx1 Capital Management first reported a position in TCRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $41.5M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

Lynx1 Capital Management held 8,019,148 shares of TScan Therapeutics worth $7.86M as of Q2 2026.
Lynx1 Capital Management left its TScan Therapeutics share count unchanged in Q2 2026.
TScan Therapeutics made up 0.91% of Lynx1 Capital Management's portfolio in Q2 2026, its #7 holding.
Lynx1 Capital Management first reported a position in TScan Therapeutics in Q2 2023 and has held it in 13 quarters since.
Lynx1 Capital Management's TScan Therapeutics position peaked at $41.5M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.